2008-12-16 | Fierce Biotech

Anesiva, Inc. Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery

Posted December 16, 2008 Anesiva, Inc. Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery SOUTH SAN FRANCISCO, Calif.

2008-12-16 | Medical News Today

Pain Hurts More If The Person Hurting You Means It

Researchers at Harvard University have discovered that our experience of pain depends on whether we think someone caused the pain intentionally. In their study, participants who believed they were getting an electrical shock from another person on purpose, rather than accidentally, rated the very same shock..

2008-12-15 | Emax Health

Guidelines Identify Best Tests For Neuropathy

New guidelines developed by the American Academy of Neurology find a combination of blood tests and other specialized assessments appear to be the most helpful tests for finding the cause of neuropathy.

2008-12-15 | PR Newswire

QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy

Efficacy and Safety Study to Support Phase 3 Combination Rule Trial for NDA Submission SYDNEY, Australia and BEDMINSTER, N.J., Dec. 15 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX) , a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for...

2008-12-15 | Medgadget

Image Guided Spine Navigation Systems Improve Spine Surgeon's Screw Placement

Using infrared guided surgical positioning devices from Medtronic and BrainLAB, surgeons at the Mayo Clinic in Florida were able to place screws during spinal surgeries with much higher precision than doing it manually.

2008-12-15 | Forbes.com

BioDelivery Sciences Submits REMS for ONSOLIS to FDA for Approval

BioDelivery Sciences International, Inc., (NASDAQ:BDSI) announced that it has resubmitted its New Drug Application (NDA) for the company's lead product ONSOLIS(TM) to the Food and Drug Administration (FDA).

2008-12-15 | Pharmacy Choice

FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation

WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has approved LUSEDRA(TM) (fospropofol disodium) Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in adult patients...

2008-12-14 | NewsRx

New findings from University of Technology in the area of complex regional pain syndrome published

(NewsRx.com) -- A new study, 'Central processing of tactile and nociceptive stimuli in complex regional pain syndrome,' is now available. "Patients with complex regional pain syndrome (CRPS) suffer from continuous regional limb pain and from hyperesthesia to touch and pain.

2008-12-14 | Medical News Today

Easing Back Pain Through Weights, Not Aerobics

People who use weight training to ease their lower back pain are better off than those who choose other forms of exercise such as jogging, according to a University of Alberta study.

2008-12-12 | redOrbit

The Profound Effects of Numbing Agents

A large proteomics study on the brains of newborn mice provides more evidence that numbing drugs often used in obstetric or pediatric medicine can have profound and long-term negative effects, even after minimal exposure.

2008-12-12 | Medical News Today

Major Pain Research Funding Decline At NIH

Federal funding for pain research is declining sharply, more than 9 percent a year since 2003, according to a new study published in The Journal of Pain.

2008-12-11 | The Wall Street Journal

What You Don't Know About a Drug Can Hurt You

There's a common assumption that when a drug makes it to market, it has run a rigorous gantlet of testing and proper disclosure. Testing, yes. Disclosure -- not necessarily.

2008-12-11 | Pharma Live

Pain Therapeutics Receives Complete Response Letter From FDA for Remoxy

SAN MATEO, Calif., December 11, 2008 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of oxycodone.

2008-12-11 | Medical News Today

Irritable Bowel Syndrome Can Have Genetic Causes

Irritations of the bowel can have genetic causes. Researchers at the Institute of Human Genetics at Heidelberg University Hospital have discovered this correlation.

2008-12-11 | Med Compare

Government Survey Shows 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine

Source: NIH/National Center for Complementary and Alternative Medicine Approximately 38 percent of adults in the United States aged 18 years and over and nearly 12 percent of U.

2008-12-11 | Medical News Today

Fat Cells Treat Spinal Cord Injury

A study published in the current issue of CELL TRANSPLANTATION (Vol.17, No. 8) suggests that mature adipocytes - fat cells - could become a source for cell replacement therapy to treat central nervous system disorders.

2008-12-11 | Med Compare

Surge in Older Cancer Survivors Expected as Baby Boomers Age

Source: University of Connecticut Oncologists, geriatricians, primary care providers increasingly challenged to provide timely and appropriate post-treatment care to older cancer survivors STORRS, CT The United States could be faced with a national health care crisis in the coming decades as the country's...

2008-12-11 | Baltimoresun.com

Military tries 'battlefield' acupuncture to ease pain

ANDREWS AIR FORCE BASE - Using ancient Chinese medical techniques, a small team of military doctors here has begun treating wounded troops suffering from severe or chronic pain with acupuncture.

2008-12-10 | Genetic Engineering & Biotechnology News

2 common diabetes drugs double the risk of fractures in women

EUREKALERT Contact: Kim Barnhardt kim.barnhardt@cma.ca 613-731-8610 x2224 Canadian Medical Association Journal Long-term thiazolidinedione use appears to reduce bone density Two common diabetes drugs rosiglitazone and pioglitazone are linked to higher fracture rates in women, according to a meta-analysis in..

2008-12-10 | Drug Topics

Grape Component Could Help Alleviate Back Pain

Resveratrol protects intervertebral disc...

2008-12-10 | Market Watch

Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)

Fewer Patients on Treatment Experienced a New...

2008-12-10 | Medical News Today

Encore Therapeutics Inc. Demonstrates Proof Of Concept For A Long-Acting Buprenorphine Depot For Pain And Drug Abuse Therapy (ETI-311)

Encore Therapeutics Inc. (ETI) today reported that ETI-311, the company's novel long-acting depot for buprenorphine, produced clinically relevant plasma levels of the drug over 3-7 days when administered by intradermal injection in dog studies.

2008-12-10 | Medical News Today

AcelRx Pharmaceuticals Reports Positive Results From A Phase 2 Clinical Trial Of Sublingual Sufentanil NanoTabs(TM) In Treating Post-Operative Pain

AcelRx Pharmaceuticals, Inc. announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery.

2008-12-09 | Reuters Industries

UPDATE 2-US advisers back Genzyme therapy for knee pain

(Recasts first paragraph; adds Genzyme comments, sales figures, competitors, byline; updates stock price) By Lisa Richwine GAITHERSBURG, Md., Dec 9 (Reuters) - A U.

2008-12-09 | Health Care Renewal

MRI and CT - the Curse of Incidentalomas

In 2001, 225 leading general internists were asked to rank 30 medical innovations in terms of their importance for patient care (see Health Affairs article here).

2008-12-09 | Science Centric

Clinical trial participants value personalised, accurate information about study results

Participants in clinical trials report being satisfied with personalised, accurate communication of results by study investigators soon after the study findings are released publicly, according to a report in the December issue of Archives of Neurology, one of the JAMA/Archives journals.

2008-12-09 | MarketWatch, Inc.

Dyloject(TM) Significantly Reduces Moderate-to-Severe Pain in Pivotal Phase 3 Orthopedic Surgical Trial

Trial Successful, Javelin Pharmaceuticals on Track to Submit New Drug Application to US FDA in 2009 CAMBRIDGE, Mass., Dec 09, 2008 (BUSINESS WIRE) -- Javelin Pharmaceuticals (JAV: javelin pharmaceuticals inc com News , chart , profile , more Last: 1.05+0.11+11.70% 4:05pm 12/19/2008 Delayed quote data Add to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: JAV 1.05, +0.11, +11.7%) announced today that its US product candidate Dyloject(TM) (diclofenac sodium for injection) met primary efficacy endpoints with robust statistical....

2008-12-09 | Newswise

Cancer Drug Arouses Hope for Patients Suffering with Scleroderma

Newswise A convergence of research has created a great deal of speculation on the far-reaching implications of Gleevec for patients suffering with the autoimmune disease scleroderma.

2008-12-09 | Medical News Today

Award-Winning Approach Will Help Thousands Of People With Upper Limb Disorders Return To Work, UK

The University of Huddersfield has won a prestigious award from medical research charity BUPA for new research which will help to stem the rising tide of employee absence that results from musculoskeletal conditions.

2008-12-09 | Medical News Today

Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Positive Results Of Phase III Study Of Milnacipran For The Management Of Fibromyalgia

Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for the management of fibromyalgia.

2008-12-08 | American Medical News

Research urged for medication overuse headaches

The problem is common, and advocates are seeking additional investigation into causes and treatments.

2008-12-07 | Pharma Live

Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications

WASHINGTON, December 05, 2008/PRNewswire-USNewswire/- The Product Stewardship Institute (PSI) convened its second earlier this week in Washington, DC to discuss ways to improve the disposal of unused medications to combat increasing rates of prescription drug abuse, accidental poisonings, and environmental...

2008-12-07 | Medical News Today

Alkermes Initiates Clinical Trial For ALKS 33, A Novel Oral Molecule With Potential Benefits In Addiction And Other CNS Disorders

Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 1 study of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other central nervous system (CNS) disorders.

2008-12-07 | Medical News Today

Largest Gathering Of Neuromodulation Experts Explores Breaking Developments In Neurodevice Technologies

Leading researchers and clinicians from the field of neuromodulation assembled today at the 12th annual meeting of the North American Neuromodulation Society (NANS), continuing until December 7 in Las Vegas, NV.

2008-12-06 | The Acorn

Guidelines for neuropathic pain sufferers

Almost everyone is familiar with the sensation of physical pain. However, did you know that there are different types of pain? One type, known as acute pain, results from injury or surgery and typically goes away when normal healing occurs.

2008-12-06 | MarketWatch, Inc.

Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress

PARSIPPANY, N.J., Dec 06, 2008 /PRNewswire via COMTEX/ -- New Sustained-Release Analgesic Significantly Reduces Postop Pain, Opioid Use, and Reduces Opioid Related Adverse Events Compared to Gold Standard Pain Medication

2008-12-06 | Salt Lake Tribune

Utah Patients Who Need Pain Pills Will be Scrutinized

Utah patients who need pain pills will be scrutinized far more closely as the state attempts to halt a rash of overdose deaths. If you get a prescription, expect to be randomly tested for illegal drugs...

2008-12-06 | Medical News Today

American Values Blamed For Health-Care Crisis

To heal our ailing health care system, we need to stop thinking like Americans. That's the message of two articles by UCLA's Dr. Marc Nuwer, a leading expert on national health care reform, published this week in Neurology, the journal of the American Academy of Neurology.

2008-12-05 | Ortho SuperSite

Patients with degenerative disc disease genetically different than those without the condition

Study finds patients with DDD are genetically predisposed to develop chronic pain after injury.

2008-12-02 | Medical News Today

Study: Patient Harm More Common With Patient-Controlled Pain Medication

Intravenous patient-controlled analgesia (PCA) allows patients to control their own pain medication, but a new study published in the December 2008 issue of The Joint Commission Journal on Quality and Patient Safety shows that errors related to this practice are four times more likely to result in patient...

2008-12-01 | Topix

New Migraine Drug Shows Promise

A drug called telcagepant proved safe and effective in treating migraines and caused fewer side effects than the widely-used migraine drug zolmitriptan , according to a study conducted by drug maker Merck & Co.

2008-12-01 | Silicin Valley Sanjose Business Journal

TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects

/PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, demonstrated a statistically significant reduction in spontaneous pain, hyperalgesia (abnormally increased pain state) and allodynia (pain...

2008-11-29 | Medical News Today

Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain

Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain.

2008-11-26 | EurekAlert!

Baffling chronic pain linked to rewiring of brain

CHICAGO --- Scientists peered at the brains of people with a baffling chronic pain condition and discovered something surprising. Their brains looked like an inept cable guy had changed the hookups, rewiring the areas related to emotion, pain perception and the temperature of their skin.

2008-11-26 | The Society for Neuroscience

Interleukin-18-Mediated Microglia/Astrocyte Interaction in the Spinal Cord Enhances Neuropathic Pain Processing after Nerve Injury

Interleukin (IL)-18 is an important regulator of innate and acquired immune responses. Here we show that both the IL-18 and IL-18 receptor (IL-18R), which are induced in spinal dorsal horn, are crucial for tactile allodynia after nerve injury.

2008-11-26 | Science Centric

Pain is in the eyes of the beholder

By manipulating the appearance of a chronically achy hand, researchers have found they could increase or decrease the pain and swelling in patients moving their symptomatic limbs.

2008-11-26 | American Digital Networks

Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain

COLLEGEVILLE, Pa. & TARRYTOWN, N.Y.-(Business Wire)-November 26, 2008 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that a phase 3 clinical study investigating RELISTOR� (methylnaltrexone bromide) subcutaneous injection to treat opioid-induced constipation (OIC) in patients with chronic, non-cancer pain achieved statistical significance...

2008-11-25 | Nanowerk

Nanoengineered hospital-on-a-chip could revolutionize battlefield medicine

battlefield of the future may react differently to combat injuries, providing instant treatment to wounded soldiers even before a medic reaches their side.

2008-11-25 | Corante

NIO Unveils Top 10 Neuroscience Trends for 2009

Here are ten emerging areas of neuroscience that will impact the future of treatments for brain and nervous system which were published as a result of the cutting edge research being presented at the Society for Neuroscience Conference held in Washington DC last week.

2008-11-25 | Biotechnology Healthcare

Sodium Oxybate Decreased Pain, Fatigue, and Improved Daily Function for Patients with Fibromyalgia in Phase 3 Trial

Sodium Oxybate Decreased Pain, Fatigue, and Improved Daily Function for Patients with Fibromyalgia in Phase 3 Trial PALO ALTO, Calif., and BRUSSELS, Belgium, Nov.